Jianan Gong

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds

Ming-Jie Luo, Michelle Palmieri, Chris D Riffkin, Anuratha Sakthianandeswaren, Tirta Mario Djajawi, Yumiko Hirokawa, Victoria Shuttleworth, David H Segal, Christine A White, Duong Nhu, Guillaume Lessene, Margaret Lee, Peter Gibbs, David CS Huang, Oliver M Sieber, Jia-nan Gong

Journal article  |  2020  |  CELL DEATH & DISEASE

Novel targets are required to improve the outcomes for patients with colorectal cancers. In this regard, the selective inhibitor o..

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  BLOOD

There is a Blood Commentary on this article in this issue.

BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines

Sarah T Diepstraten, Catherine Chang, Lin Tai, Jia-nan Gong, Ping Lan, Alexander C Dowell, Graham S Taylor, Andreas Strasser, Gemma L Kelly

Journal article  |  2020  |  BLOOD ADVANCES

Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis. To counter this, BH3-mimetic drugs that ..

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Charis E Teh, Jia-Nan Gong, David Segal, Tania Tan, Cassandra J Vandenberg, Pasquale L Fedele, Michael SY Low, George Grigoriadis, Simon J Harrison, Andreas Strasser, Andrew W Roberts, David CS Huang, Garry P Nolan, Daniel HD Gray, Melissa E Ko

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

Multiple myeloma is an incurable and fatal cancer of immunoglobulin-secreting plasma cells. Most conventional therapies aim to ind..

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Anne Slomp, Laura M Moesbergen, Jia-nan Gong, Marta Cuenca, Peter A von dem Borne, Pieter Sonneveld, David CS Huang, Monique C Minnema, Victor Peperzak

Journal article  |  2019  |  BLOOD ADVANCES

Prosurvival BCL-2 family proteins are potent inhibitors of apoptosis and often overexpressed in lymphoid malignancies. In multiple..

Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting

Anne Slomp, Laura Moesbergen, Jia-nan Gong, Marta Cuenca, Peter von dem Borne, Pieter Sonneveld, David Huang, Monique Minnema, Victor Peperzak

Conference Proceedings  |  2019  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

Piers Blombery, Richard W Birkinshaw, Tamia Nguyen, Jia-nan Gong, Ella R Thompson, Zhen Xu, David A Westerman, Peter E Czabotar, Michael Dickinson, David CS Huang, John F Seymour, Andrew W Roberts

Journal article  |  2019  |  BRITISH JOURNAL OF HAEMATOLOGY

RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

Rachel Thijssen, Mary Ann Anderson, Charis Teh, Marie Trussart, Piers Blombery, Richard Birkinshaw, Jianan Gong, Daniel Gray, David Huang, Andrew Roberts

Conference Proceedings  |  2019  |  EXPERIMENTAL HEMATOLOGY

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Richard W Birkinshaw, Jia-nan Gong, Cindy S Luo, Daisy Lio, Christine A White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J Majewski, Rachel Thijssen, Andrew W Roberts, David CS Huang, Peter M Colman, Peter E Czabotar

Journal article  |  2019  |  NATURE COMMUNICATIONS

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment ..

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel HD Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2019  |  CANCER DISCOVERY

The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leuk..